TransMedics Group, Inc. (NASDAQ:TMDX) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. lifted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 1.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,814,442 shares of the company's stock after purchasing an additional 29,798 shares during the period. Vanguard Group Inc. owned 5.56% of TransMedics Group worth $99,341,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Comerica Bank purchased a new stake in shares of TransMedics Group during the 3rd quarter worth approximately $34,000. Global Retirement Partners LLC purchased a new position in TransMedics Group in the 3rd quarter valued at approximately $38,000. Cutler Group LLC CA boosted its holdings in TransMedics Group by 600.0% in the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company's stock valued at $38,000 after purchasing an additional 600 shares during the period. Ancora Advisors LLC bought a new position in TransMedics Group in the 1st quarter valued at $38,000. Finally, First Horizon Advisors Inc. boosted its holdings in TransMedics Group by 45.1% in the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company's stock valued at $41,000 after purchasing an additional 169 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. JPMorgan Chase & Co. raised their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the company an "overweight" rating in a report on Tuesday, February 27th. Oppenheimer lifted their price objective on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an "outperform" rating in a report on Tuesday, February 27th. Piper Sandler began coverage on shares of TransMedics Group in a research report on Thursday, March 28th. They issued an "overweight" rating and a $95.00 target price on the stock. Finally, Morgan Stanley lifted their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $102.00.

Insider Activity at TransMedics Group

In related news, insider Tamer I. Khayal sold 10,000 shares of the business's stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $80.41, for a total transaction of $804,100.00. Following the transaction, the insider now owns 14,375 shares in the company, valued at $1,155,893.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Edward M. Basile sold 7,157 shares of the business's stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total transaction of $618,221.66. Following the sale, the director now owns 8,350 shares of the company's stock, valued at $721,273. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 10,000 shares of the business's stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $80.41, for a total transaction of $804,100.00. Following the sale, the insider now directly owns 14,375 shares in the company, valued at approximately $1,155,893.75. The disclosure for this sale can be found here. Insiders have sold 97,896 shares of company stock worth $8,062,360 over the last 90 days. 6.70% of the stock is owned by company insiders.

TransMedics Group Trading Up 10.2 %

Shares of TMDX stock traded up $7.84 during mid-day trading on Friday, reaching $85.04. The stock had a trading volume of 1,117,719 shares, compared to its average volume of 657,415. The stock's 50-day moving average price is $82.28 and its two-hundred day moving average price is $70.58. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $99.63. The firm has a market capitalization of $2.78 billion, a PE ratio of -110.44 and a beta of 1.99. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The company had revenue of $81.20 million for the quarter, compared to analysts' expectations of $68.49 million. During the same quarter in the previous year, the company earned ($0.21) earnings per share. TransMedics Group's quarterly revenue was up 158.6% on a year-over-year basis. Equities analysts expect that TransMedics Group, Inc. will post -0.14 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.